Pre-transplant Evaluation: An Essential Step in Organ Transplantation

Jee Youna*

Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, USA

K. . . . : D a . . e ec i a; HLA ma ching; Eng a men; C m icai a; S . i a a e; Rea, e; P . . an an ca e; L ng-e mf . . . ; P . gn icfac . ; Di ea e-, eci c . c me

Ogan an anainia ife-aing cede ha e he and in ed ai si fife fe aien, i hend-age gan fai e. Hee, he cee f gan an anain eie heais na he ghand meic e-an an ea ain ce. Pe-an an ea ain e e a ain e e a aciica e in iden if nag i abe candidae f an anain, a e ing he com aibii si be een he eciien and he en ia da, and imizing an an come.

e ima & becie fhe e an an ea aini en e he afe & and e cac fhe an an ain ced e. I in e a c mehen i ea e men fb h he eci ien and he en ia d n e a a e hei medica c ndiin, facina a , and e a i abii & f an an ain i e a ain ce i e en ia f enhancing aien e eci n, minimizing he i , a cia ed i h an an ain, and maximizing he chance f ng-e m gan i a [1].

e e- an an e a a i n enc ma a e a ide ange f c ma nen, inc ding a de ai ed medica hi s e ie, hasica examina i n, diagn, ic e, and ma idici in a c ab a i n am ng hea hca e fe i na. gh hi c ma ehen i e e a a i n, hea hca e ide can ga he i a inf ha can im ac he managemen [2].

e e , f he .e- an .an e a a i n .a Mac cia .e in de e mining he .a ien , .acemen , he .an .an .ai ing i and he na deci i n-ma ing .ce . A m idi ci ina Man .an .eec i n c mui ee e ie , he e a a i n and eigh he i , and bene , bef e ma ing deci i n .ega ding he i abi i fa fandida e f .an .an an ai n.

Medica Hi, Mah, ghe ie fhe ecie, medica hi i c ad c ed, iac diag he ima Mdi ea e eading gan fai e e i ea men, medica i n, and an e e an c m bidi ie.

Physica exampina i n.: A c man ehen i e ha ica exampina i n. i e f med e a a e he eci ien e a hea h, iden if an a ign f en ia c n aindica i n, and a e, hei ne f ... ge a

Diagn, ic e: Vai, diagn, ic e, a e c nd c ed a e, he e e i s f gan fai e and he eci ien, i abi i s f an an a i n. e e e massinc de b d , i maging die (ch a a nd, CT can, MRI), and f nc i na a e men, (ch a ca diac e e ... m na s f nc i n e .) [4].

Medica hi Me e en ia gan da medica hi Mi ca ef Me ie ed en ec maibi i Mandiden if Man Mfac ha ma a ce and i inc de inf mai'n hed a ge, ca e f dea h, medica c'hdi i n, and ife Me habi.

D n c eening: Rig c eening ced e a e c nd c ed a e he en ia d n gan f nc i n and e an Winfec i maignan di ea e Lab a We, cha b dand i e wing, a e a imaging die, a e wing case f med e a a e he

 $ga \, \rlap{/}{\mathbf n} \quad i \ abi \ i \ \ \rlap{/}{\mathbf M} f \ \ldots a \, \rlap{/}{\mathbf n} \ - a \, \rlap{/}{\mathbf n} \ a \ i \ \ \rlap{/}{\mathbf n} \ [5].$

\mathbf{M}

e e an an e a ain in e c ab ain am ng ai , hea hoa e e fe i na , inc ding an an , ge n, an an neh gi, he a gi, ca di gi, . In n gi, , sth gi, cia e, and he eciai a e i ed. e e fe i na c n ib e hei ex e i eine a a ing he eci ien and e n ia d n medica, sch gica, and cia a ec en ea c men i ea, e, men [6].

E hica c \P ide a i \P - a \P a c cia e i \P he e.e. a \P - a \P e a ai , ce. Inf med c , en i bained f m b h he ecilien and he en ia d n , en ling he nde and he i , , bene , and a e nai e land and a e a i n . ce . adhe e e hica g ide ine, en ing fai ne, an a enc and e ec f he a \mathbf{A} \mathbf{A} \mathbf{A} \mathbf{A} \mathbf{A} \mathbf{A} d e -bei \mathbf{A} \mathbf{B} fa a ie i \mathbf{A} ed [7].

e da a c ec ed d ing he e e an a a a in, inc ding medica hi ie, e e ,, and m idici ina Ma, e men,, a e ana Sed ma e inf med deci i ega ding a ien, e ec i n and
i abi i Sf lan an an ai n. A m idi ci in sa an e ec i n
c mani ee e e e. he e a a i n and c ab a i e Sedecide n he
i i iza i n f 90h9(ie,)0.5()6(e)5id9()-5(i)12()0.5(n)4(d)]TEL044
e n an ei f . e6 T. TEO 9 52 Td[(m)83(e)-5(())12(8()-8(en2() din)8(g)(n)8())0.5,(e)12())13(e-)-5(a)9(n)8()5(-)7()-2.9(a)9(n)9(e)-8

- (2022) Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouf aged nanoparticles: A promising biomimetic nanoplatforms for cancer theranostics. J Control Release 348:706-722.
- Wu HH, Zhou Y, Tabata Y, Gao JQ (2019) Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release 28: 102-113.
- Yan K, Zhang J, Yin W, Harding JN, Ma F, et al. (2022) Transcriptomic heterogeneity of cultured ADSCs corresponds to embolic risk in the host. IScience 4: 104822.
- 4. Zhang W, Huang X (2022) Stem cell membrane-camouf aged targeted delivery system in tumor. Mater Today Bio 1: 100377.
- Li Y, Wu H, Jiang X, Dong Y, Zheng J, et al. (2022) New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery. Acta Pharm Sin B 12: 3215-3232.
- Ji B, Cai H, Yang Y, Peng F, Song M, et al. (2020) Hybrid membrane camoufaged copper sulfde nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. Acta Biomater 111: 363-372.
- Wang M , Xin Y , Cao H , Li W , Hua Y, et al. (2021) Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery. Biomater Sci 9:1088-1103.
- 8. Xia Q, Zhang Y, Li Z, Hou X, Feng N, et al. (2019) Red blood cell membrane-camouf aged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 9: 675-689.
- Shin MJ, Park JY, Lee DH, Khang D (2021) Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis. Int J Nanomedicine 16: 8485-8507.
- Vasanthan V, Hassanabad AF, Fedak PWM (2021) Commentary: Cell therapy for spinal regeneration-implications for recovery after complex aortic surgery. JTCVS Open 24: 45-46.